re: 454 tech and sequencing
I think 454's tech is fascinating and so do most of the techies we talk with. I am cautious of the "picks-and-shovels" trade as a rule in biotech. Because of that we don't pay much attention to the sequencing companies, so I cannot answer your question directly.
The HG project received the most press, but the real advances will be made when we map the proteasome. Companies able to effectively translate that research into products with a lower-risk clinical development profile interest us more than the companies doing the hard number crunching.
We're pulling the ripcord for the holiday season here at BSR HQ. Warmest wishes for a safe and happy holiday season and a profitable new year to everyone.
David Miller
BSR, LLC
No position in the companies mentioned at the time this was written.
Market Data 
Markets 
AI
